secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2022-08-10T23:59:59+00:00
Accession:  0001104659-22-088684
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE's FMX114 Phase 2a AD trial misses primary endpoint; shareholders reject reverse stock split
--------------------------------------------------------------------------------

- Phase 2a trial of FMX114 for mild-to-moderate atopic dermatitis did not meet primary endpoint (ADSI change at week 4, p=0.228).
- Mean ADSI reduction -60.62% for FMX114 vs -51.32% for vehicle; not statistically significant.
- CEO disappointed; company will evaluate pipeline and prioritization.
- Cash ~$43M as of June 30, 2022; $5M payment due Jan 2023 from MST franchise sale.
- Shareholders voted against reverse stock split (needed >28.9M votes, got 23.7M for).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465922088684/0001104659-22-088684-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465922088684/tm2222986d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-088684

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer